Dr. Daniel Acosta and In Vitro toxicology at the U.S. Food and Drug Administration's National Center for Toxicological Research

Amy Inselman; Fang Liu; Cheng Wang; Qiang Shi; Li Pang; William Mattes; Matthew White; Beverly Lyn-Cook; Hector Rosas-Hernandez; Elvis Cuevas; Susan Lantz; Syed Imam; Syed Ali; Dayton M. Petibone; Jennifer M. Shemansky; Rui Xiong; Yiying Wang; Priya Tripathi; Xuefei Cao; Robert H. Heflich; William Slikker

doi:10.1016/j.tiv.2019.03.003

Dr. Daniel Acosta and In Vitro toxicology at the U.S. Food and Drug Administration's National Center for Toxicological Research

Amy Inselman, Fang Liu, Cheng Wang, Qiang Shi, Li Pang, William Mattes, Matthew White, Beverly Lyn-Cook, Hector Rosas-Hernandez, Elvis Cuevas, Susan Lantz, Syed Imam, Syed Ali, Dayton M. Petibone, Jennifer M. Shemansky, Rui Xiong, Yiying Wang, Priya Tripathi, Xuefei Cao, Robert H. HeflichWilliam Slikker

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

For the past five years, Dr. Daniel Acosta has served as the Deputy Director of Research at the National Center for Toxicological Research (NCTR), a principle research laboratory of the U.S. Food and Drug Administration (FDA). Over his career at NCTR, Dr. Acosta has had a major impact on developing and promoting the use of in vitro assays in regulatory toxicity and product safety assessments. As Dr. Acosta nears his retirement we have dedicated this paper to his many accomplishments at the NCTR. Described within this paper are some of the in vitro studies that have been conducted under Dr. Acosta's leadership. These studies include toxicological assessments involving developmental effects, and the development and application of in vitro reproductive, heart, liver, neurological and airway cell and tissue models.

Original language	English (US)
Article number	104471
Journal	Toxicology in Vitro
Volume	64
DOIs	https://doi.org/10.1016/j.tiv.2019.03.003
State	Published - Apr 2020
Externally published	Yes

ASJC Scopus subject areas

Toxicology

Access to Document

10.1016/j.tiv.2019.03.003

Cite this

Inselman, A., Liu, F., Wang, C., Shi, Q., Pang, L., Mattes, W., White, M., Lyn-Cook, B., Rosas-Hernandez, H., Cuevas, E., Lantz, S., Imam, S., Ali, S., Petibone, D. M., Shemansky, J. M., Xiong, R., Wang, Y., Tripathi, P., Cao, X., ... Slikker, W. (2020). Dr. Daniel Acosta and In Vitro toxicology at the U.S. Food and Drug Administration's National Center for Toxicological Research. Toxicology in Vitro, 64, Article 104471. https://doi.org/10.1016/j.tiv.2019.03.003

Inselman, A, Liu, F, Wang, C, Shi, Q, Pang, L, Mattes, W, White, M, Lyn-Cook, B, Rosas-Hernandez, H, Cuevas, E, Lantz, S, Imam, S, Ali, S, Petibone, DM, Shemansky, JM, Xiong, R, Wang, Y, Tripathi, P, Cao, X, Heflich, RH & Slikker, W 2020, 'Dr. Daniel Acosta and In Vitro toxicology at the U.S. Food and Drug Administration's National Center for Toxicological Research', Toxicology in Vitro, vol. 64, 104471. https://doi.org/10.1016/j.tiv.2019.03.003

@article{2b1e2252f87646a5b3c39a6964111239,

title = "Dr. Daniel Acosta and In Vitro toxicology at the U.S. Food and Drug Administration's National Center for Toxicological Research",

abstract = "For the past five years, Dr. Daniel Acosta has served as the Deputy Director of Research at the National Center for Toxicological Research (NCTR), a principle research laboratory of the U.S. Food and Drug Administration (FDA). Over his career at NCTR, Dr. Acosta has had a major impact on developing and promoting the use of in vitro assays in regulatory toxicity and product safety assessments. As Dr. Acosta nears his retirement we have dedicated this paper to his many accomplishments at the NCTR. Described within this paper are some of the in vitro studies that have been conducted under Dr. Acosta's leadership. These studies include toxicological assessments involving developmental effects, and the development and application of in vitro reproductive, heart, liver, neurological and airway cell and tissue models.",

author = "Amy Inselman and Fang Liu and Cheng Wang and Qiang Shi and Li Pang and William Mattes and Matthew White and Beverly Lyn-Cook and Hector Rosas-Hernandez and Elvis Cuevas and Susan Lantz and Syed Imam and Syed Ali and Petibone, {Dayton M.} and Shemansky, {Jennifer M.} and Rui Xiong and Yiying Wang and Priya Tripathi and Xuefei Cao and Heflich, {Robert H.} and William Slikker",

note = "Funding Information: Human iPSC-CMs hold great potential for studying genotype-phenotype associations ( Sayed et al., 2016 ). Accordingly, a project is under development to identify and understand the molecular and genetic mechanisms underlying tyrosine kinase inhibitor (KI)-induced cardiotoxicity using 250 lines of hiPSC-CMs from the National Heart Lung Blood Institute (NHLBI) HyperGEN cohort. While the development of KIs has revolutionized cancer treatment ( Chen et al., 2008 ), a subset of patients treated with KIs develops cardiac dysfunction and heart failure. For many patients, KI-induced cardiotoxicity counters the benefits of these life-saving anti-cancer reagents. As little is known about the underlying pathophysiology and risk factors for KI-induced cardiotoxicity ( Ewer and Ewer, 2013 ), scientists from the Medical College of Wisconsin proposed to use hiPSC-CMs to identify genetic markers that contribute to the variability in the responses to KIs. The project has been recently funded by NHLBI with NCTR researchers as collaborators on the project. Phenotypic analysis, expression analysis, and functional assays will be performed to identify functional networks for KI-induced cardiotoxicity. GWAS and whole exome data will be used to determine variants associated with KI-induced cardiotoxic response. This project is in line with interests of NCTR in identifying novel biomarkers for drug-induced cardiotoxicity and applying innovative systems biology approaches to advance drug safety evaluation. Publisher Copyright: {\textcopyright} 2019",

year = "2020",

month = apr,

doi = "10.1016/j.tiv.2019.03.003",

language = "English (US)",

volume = "64",

journal = "Toxicology in Vitro",

issn = "0887-2333",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Dr. Daniel Acosta and In Vitro toxicology at the U.S. Food and Drug Administration's National Center for Toxicological Research

AU - Inselman, Amy

AU - Liu, Fang

AU - Wang, Cheng

AU - Shi, Qiang

AU - Pang, Li

AU - Mattes, William

AU - White, Matthew

AU - Lyn-Cook, Beverly

AU - Rosas-Hernandez, Hector

AU - Cuevas, Elvis

AU - Lantz, Susan

AU - Imam, Syed

AU - Ali, Syed

AU - Petibone, Dayton M.

AU - Shemansky, Jennifer M.

AU - Xiong, Rui

AU - Wang, Yiying

AU - Tripathi, Priya

AU - Cao, Xuefei

AU - Heflich, Robert H.

AU - Slikker, William

N1 - Funding Information: Human iPSC-CMs hold great potential for studying genotype-phenotype associations ( Sayed et al., 2016 ). Accordingly, a project is under development to identify and understand the molecular and genetic mechanisms underlying tyrosine kinase inhibitor (KI)-induced cardiotoxicity using 250 lines of hiPSC-CMs from the National Heart Lung Blood Institute (NHLBI) HyperGEN cohort. While the development of KIs has revolutionized cancer treatment ( Chen et al., 2008 ), a subset of patients treated with KIs develops cardiac dysfunction and heart failure. For many patients, KI-induced cardiotoxicity counters the benefits of these life-saving anti-cancer reagents. As little is known about the underlying pathophysiology and risk factors for KI-induced cardiotoxicity ( Ewer and Ewer, 2013 ), scientists from the Medical College of Wisconsin proposed to use hiPSC-CMs to identify genetic markers that contribute to the variability in the responses to KIs. The project has been recently funded by NHLBI with NCTR researchers as collaborators on the project. Phenotypic analysis, expression analysis, and functional assays will be performed to identify functional networks for KI-induced cardiotoxicity. GWAS and whole exome data will be used to determine variants associated with KI-induced cardiotoxic response. This project is in line with interests of NCTR in identifying novel biomarkers for drug-induced cardiotoxicity and applying innovative systems biology approaches to advance drug safety evaluation. Publisher Copyright: © 2019

PY - 2020/4

Y1 - 2020/4

N2 - For the past five years, Dr. Daniel Acosta has served as the Deputy Director of Research at the National Center for Toxicological Research (NCTR), a principle research laboratory of the U.S. Food and Drug Administration (FDA). Over his career at NCTR, Dr. Acosta has had a major impact on developing and promoting the use of in vitro assays in regulatory toxicity and product safety assessments. As Dr. Acosta nears his retirement we have dedicated this paper to his many accomplishments at the NCTR. Described within this paper are some of the in vitro studies that have been conducted under Dr. Acosta's leadership. These studies include toxicological assessments involving developmental effects, and the development and application of in vitro reproductive, heart, liver, neurological and airway cell and tissue models.

AB - For the past five years, Dr. Daniel Acosta has served as the Deputy Director of Research at the National Center for Toxicological Research (NCTR), a principle research laboratory of the U.S. Food and Drug Administration (FDA). Over his career at NCTR, Dr. Acosta has had a major impact on developing and promoting the use of in vitro assays in regulatory toxicity and product safety assessments. As Dr. Acosta nears his retirement we have dedicated this paper to his many accomplishments at the NCTR. Described within this paper are some of the in vitro studies that have been conducted under Dr. Acosta's leadership. These studies include toxicological assessments involving developmental effects, and the development and application of in vitro reproductive, heart, liver, neurological and airway cell and tissue models.

UR - http://www.scopus.com/inward/record.url?scp=85081110306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081110306&partnerID=8YFLogxK

U2 - 10.1016/j.tiv.2019.03.003

DO - 10.1016/j.tiv.2019.03.003

M3 - Review article

C2 - 31628011

AN - SCOPUS:85081110306

SN - 0887-2333

VL - 64

JO - Toxicology in Vitro

JF - Toxicology in Vitro

M1 - 104471

ER -

Dr. Daniel Acosta and In Vitro toxicology at the U.S. Food and Drug Administration's National Center for Toxicological Research

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this